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Chronic Atrial Fibrillation
Success of Serial Cardioversion Therapy and Safety of Oral Anticoagulat
MSc; A. T. Marcel Gosselink'MD: Freek W.
Jo han
Backgrounds
for treatment of atrial 
cacy has not been
:sion is often used 
its long-term effi-
Objectives: To determine the long-term success rate of
the serial approach in patients with
chronic atrial fibrillation, to identify factors that predict
its success, and to assess the efficacy and safety of oral 
anticoagulation in these patients.
Methods: Patients with chronic (>24  hours) atrial fi­
brillation received anticoagulant therapy for at least 4 
weeks prior to electrical cardioversion. No prophylactic 
antiarrhythmic agent was given after the first shock. Re­
lapses were managed by using repeated cardioversions, 
after which serial antiarrhythmic drug therapy was started. 
Treatment with anticoagulants was withdrawn after 4 
weeks of sinus rhythm.
Results: Two hundred 
lowed up
ty-six were fol-
m c a n of 3.7±1.6 years. The actu­
arial cumulative percentages of patients who main-
«ta
tained sinus rhythm after serial cardioversion treatment 
was 42% and 27% after 1 and 4 years, respectively. Mul­
tivariate analysis showed that factors that were associ­
ated with failure of this approach included duration of 
atrial fibrillation that exceeded 36 months (risk ratio, 5.0; 
P<.001), poor exercise tolerance (functional class III; risk 
ratio, 1.8; P=.001), and age older than 56 years (risk ra­
tio, 1.5; P=.04). The anticoagulation level (interna­
tional normalized ratio, 2.4-4.8) was associated with an 
incidence of thromboembolic events and bleeding com­
plications of 0.2% and 1.5%, respectively.
Conclusions: Many patients with chronic atrial fibril­
lation failed to respond to the serial electrical cardiover­
sion strategy. However, in younger patients with a fair 
exercise tolerance and a duration of atrial fibrillation 
shorter than 36 months, this approach may be worth­
while. In addition, thromboembolic events were in­
frequent in the patients who were subjected to this 
regimen.
Arch Intern Med. 1996;156:2585-2592
From the Departments of 
Cardiology, Tlwraxeenter,
HE DC ELECTRICAL cardio- These drawbacks preclude a reliable
version is an effective and assessment of the patient characteristics
safe m ethod to obtain that determine the long-term prognosis
sinus rhythm in patients for atrial fibrillation. Thus, the notion
with chronic atrial fibrilla- that arrhythmia outcome is favorable
lion, but the procedure is not always sue- in about half of the patients may be
cessful.u  To prevent a recurrence of erroneous.
atrial fibrillation, antiarrhythmic drug
quent relapses
The aini of thè present prospective 
study was 2-fold: (1) lo investigate thè
of atrial fibrillation oc- long-term outcome of a serial electrical car-
cur,1'10 and occasionally drug treatment is 
associated with adverse events.11,u How-
dioversion approach combined with se­
rial prophylactic antiarrhythmic drug
ever, patients may remain at risk for a therapy and determine the factors thatpre-
thromboembolic event after recurrence diet its success and (2) to assess the effi-
of the arrhythmia, while they are already cacy and safety of oral anticoagulation
no longer receiving warfarin sodium. Up therapy in patients with chronic atrial fi-
Univcrsity Hospital Groningen, untii now there have been only limited brillation by using this strategy.
Groningen, the Netherlands 
(Dr:s Van (leider, Crijns, 
Tieleman, Bhigemann, 
Cfosselink, and Lie and 
Mr De Kami, and University 
H os pit al Nij me gen, N ij in ege n,
data on the long-term outcome of serial 
electrical cardioversion therapy.15,14 
Moreover, previous studies usually did 
not evaluate patients who did not 
respond to electrical cardioversion, and
the Netherlands (Dr Verheugc). this might have caused selection bias.
See Patients and Methods 
on next page
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PA TIENTS AND METHODS the day of electrical cardioversion, a 2-dimensional trans- 
thoracie echocardiographic assay was clone. During this pro­
cedure, left and right atrial dimensions, as well as left ven-
In the course of 7 years (January 1986-January 1993), 426 tricular dimensions, were determined according to the
consecutive patients with chronic atrial fibrillation were re- method of Schiller et a l. '1 Electrical nsion was per-
ferred to our hospital for treatment. Criteria for chronic- formed without antiarrhythmic drug pretreatment in the
ity of atrial fibrillation were at least 2 electrocardiographic postabsorptive state during light general anesthesia by us-
documentations ancl continuous presence on a 24-hour ing 20 mg of etomidate intravenously. Two investigators
Holter recording. Neither patient age nor duration of atrial (I.C.V.G. and A.T.M.G.) managed all procedures at the coro-
fibrillation was an exclusion criterion for participation in nary care unit. A calibrated defibrillator (Hewlett Packard
the study. Exclusion criteria were New York Heart Asso­
ciation class IV for exercise tolerance (n=60), unstable an-
43120-A, Hewlett-Packard Co, Palo Alto, Calif) that could 
store 360 J of energy was used as the cardioverter device.
gina pectoris (n= 10), or acute myocardial infarction less One paddle was placed in the second intercostal space on 
than 4 weeks earlier (n=14). Patients were also not in- the right side parasternally; the other was placed in a left- 
eluded in this series if they had a relapse of chronic atrial sided lateral position along the midaxillary line. Accord-
fibrillation while they were receiving an antiarrhythmic drug 50 J
prior to the inclusion into the present study (n= 106). The Thereafter, the energy load of successive shocks was doubled
remaining 236 patients were subject to evaluation; some 
of them have been described previously.2,7'1'1' The study was
until sinus rhythm was restored or after 2 attempts with
360 J. :k rhythm monitoring was secured by us-
approved by the local institutional review board, and writ- ing telemetry for 8 to 24 hours. Successful cardioversion
ten informed consent was given by all patients.
Electrical cardioversion was the principal treatment
was defined as the maintenance of sinus rhythm more than 
8 hours after cardioversion. If, after the first electrical car-
of atrial fibrillation. After the first cardioversion, no anti- dioversion procedure, sinus rhythm was accomplished, pa- 
arrhythmic drug therapy was started. In contrast, follow- tients did not receive an antiarrhythmic drug. At any rate,
ing a relapse of the arrhythmia, our serial prophylactic an 1 ,3 , and 6 months after discharge, patients were schecl-
tiarrhythmic drug strategy was applied. In the case of failure ulecl for outpatient department visits. Thereafter, patients
to reestablish sinus rhythm, the rate control alternative was were seen each 6 months. Treatment with anticoagulants
adopted (Figure 1). Each electrical cardioversion was per- was discontinued if sinus rhythm remained present for more
formed on an elective basis. The protocol has been cle- than 1 month after its restoration, except in those who
scribed before.2 In short, patients received warfarin or a de- required prolonged anticoagulation (eg, in the case of mi-
rivative at least 4 weeks prior to the procedure. The target tral stenosis). If atrial fibrillation relapsed, patients uncler-
prothrombin time was an international normalized ratio of went a repeated electrical cardioversion as soon as pos-
2.4 to 4.8. Efficacy of anticoagulation was monitored by a sible. Those who clearly thought that the recurrence of atrial
regional thrombosis center. Such services are specialized fibrillation lasted less than 24 hours were subjected to car-
in the monitoring ofcoumarin therapy for outpatients. On dioversion without preceded anticoagulation; the others
MfflM MMft*
RESULTS
OUTCOME OF SERIAL CARDIOVERSIONS
Baseline characteristics of the patients are presented in 
Table 1 . The mcan±SD follow-up of the. 236 patients 
was 3.7± 1.6 (range, 0.2-7.0) years. Figure 2  shows the 
percentage of patients who maintained sinus rhythm af­
ter a single cardioversion and after serial cardiover­
sions. The actuarial cumulative percentages of patients 
who maintained sinus rhythm was 42%, 38%, ancl 27% 
after 12,24, and 48 months, respectively. The steep drop 
in sinus rhythm maintenance probability at “0" months 
is an illustration of an unsuccessful cardioversion ancl an 
early relapse rate. The gradual decline in time shows the 
delay of recurrence of atrial fibrillation in the group of 
patients who were treated with the serial cardioversion 
approach. Long-term maintenance of sinus rhythm was 
achieved in 74 patients: 36 were not treated with anti­
arrhythmic drugs, 7 received sotalol, 7 received flecain- 
ide, and 24 received amioclarone. Figure 3  shows that 
half of the successfully treated patients maintained si­
nus rhythm after only 1 or 2 cardioversions and without 
prophylactic drug therapy. The number of patients who
took advantage of electrical cardioversion did not in­
crease after the fourth procedure (Figure 3). Baseline char­
acteristics of the patients who kept sinus rhythm after 
serial cardioversions compared with those who did not, 
including the results of the univariate analysis, arc also 
listed in Table 1. Multivariate analysis revealed that the 
previous duration of the arrhythmia, New York Heart As­
sociation class for exercise tolerance, and age were sig­
nificantly associated with outcome. Previous arrhyth­
mia duration and age showed a nonlinear distribution of 
estimated coefficients; therefore, multivariate analysis was 
done after subdividing the groups as follows: age younger 
and older than 56 years and duration of the arrhythmia 
less than 3, 3 to 36, and more than 36 months. The New 
York Heart Association classification was divided into a 
group of patients in class I or II ancl in class III. Multi­
variate analysis showed that compared with the refer­
ence group, patients with a duration of the arrhythmia 
between 3 and 36 months showed a moderately el­
evated risk ratio, whereas those with a duration of greater 
than 36 months had a strongly increased risk ratio of fail­
ure of therapy. A moderately elevated risk ratio was also 
found in patients older than 56 years and in patients in 
the functional class III (Table 2).  Figure 4  shows the
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were given warfarin for at least 1 month. Patients with sue- fibrillation, incidence of thromboembolic complications, oc-
eessive recurrences of the arrhythmia were treated con­ currence of bleeding complications due to the use of antico-
secutively with 3 different prophylactic antiarrhythmic agulants, progression of congestive heart failure, and, fi- 
drugs. Until 1989, we used flecainide acetate as the initial nally, antiarrhythmic drug-related adverse events. Requirement 
agent, but the results of the Cardiac Arrhythmia Suppres- for pacemaker implantation because of a sick sinus syn- 
sion Trial16 turned our preference to sotalol hydrochlo- drome or bundle of His ablation was also scored. The over­
ride (160-320 mg/d); we used flecainide acetate (200-300 all and cardiovascular mortality rates were recorded.
mg/d) as the second agent, and finally, we used amioda- A 2-sided probability level of less than .05 was con-
ificance. For the com-rone hydrochloride (600 mg/d for 4 weeks, followed by 200- sidered to indicate statistical
300 mg/d). Amiodarone therapy was started at 4 or more parison of clinical characteristics associated with long-
weeks prior to a repeated electrical cardioversion. Pa- term m aintenance of sinus rhythm  and success of
tients with a relapse of atrial fibrillation after more than 1 cardioversion, a x 2 test, Wilcoxon-Mann-Whitney U  test,
year of sinus rhythm (ie, a so-called late recurrence) un- or Student t test, if appropriate, were used. Cumulative rates
derwent electrical cardioversion without subsequent pro­
phylactic antiarrhythmic drug treatment or without a change
for the time to recurrence of atrial fibrillation were esti­
mated by using the Kaplan-Meier method. Groups were
of the antiarrhythmic drug that was eventually used. Pa- compared by using the log rank statistic with regard to cu-
tients in whom a certain antiarrhythmic drug was contra- mulative rates for the time to an event. To determine pa-
indicated continued to receive the next agent in our se- rameters that were related to maintenance of sinus rhythm
quence. The inclusion started on the day of the first after cardioversion(s), Cox proportional hazards regres-
cardioversion, and follow-up was completed in the case of sion analysis was performed. Only covariates with P val- 
death or on January 1, 1994, whichever came first.
Conditions for acceptance of atrial fibrillation in-
ues of .20 or less in the univariate analysis were entered in 
this model. Variables, modeled as continuous, were as-
cluded failure with amiodarone therapy, drug-related side sessed by determining the quartiles of their distribution, 
effects, completely asymptomatic arrhythmia experience af- Subsequently, coefficients for each quartile were deter-
ter cardioversion(s), or refusal of another electrical car­
dioversion. In these patients, the ventricular rate control 
of atrial fibrillation was pursued by digitalis and, if neces­
sary, with additional verapamil hydrochloride, diltiazem 
hydrochloride, or a (3-blocker with the aim to obtain a rest-
mined. In the case of a linear trend of the estimated coef­
ficients of the different groups, the variable was intro­
duced as continuous. If no linearity could be demonstrated, 
the variable was categorized by taking together the quar­
tiles with similar coefficients. By using the same method,
ing heart rate of less than 100 beats per minute. Bundle of parameters that related to successful cardioversion were de-
His ablation with implantation of a pacemaker was of- termined by using logistic regression analysis. Adjusted risk
fered to the patient if symptoms of palpitations were se- ratios and 95% confidence intervals (CIs) are presented, 
vere or in the case of progression or persistence of tachy- For calculations, commercially available computer soft- 
cardia-related heart failure.
Cardiovascular events included recurrence of atrial
ware (Statistical Analysis System version 6.10, SAS Insti­
tute, Cary, NC) was used.
mm
significance of the presence of either 1 or more risk fac- a 23- (95% Cl, 8-66; P<.001) increased failure rate,
tors compared with the absence of risk factors in re la- respectively, compared with an arrhythmia existence of 
tion to outcome. The delay of arrhythmia acceptance was less than 3 months. The Kaplan-Meier survival analysis 
most pronounced in patients without or with only 1 risk showed that after a single cardioversion without prophy­
lactic antiarrhythmic drug use, 24 patients (10%) main­
tained long-term sinus rhythm (Figure 2). In the remain­
ing 212 patients, either the first electrical cardioversion 
was unsuccessful (n=93) or there was a relapse of atrial 
illation (n=119). Univariate analysis showed that du­
ration of the arrhythmia, patients’ age, and presence of 
hypertension were significant determinants for a re- 
irst cardioversion was successful in 143 patients lapse of atrial fibrillation after a single shock and with-
actic drug treatment. As given in Table 3,
in only 5 patients, after 2 shocks (50 and 100 J) in 43 these parameters retained significance after multivari-
CLINICAL CHARACTERISTICS ASSOCIATED
WITH LONG-TERM MAINTENANCE 
OF SINUS RHYTHM AFTER THE SINGLE
CARDIOVERSION PROCEDURE
(61%). Sinus rhythm was restored after 1 shock (50 J)
patients, after 3 shocks (50, 100, and 200 j)  in 47 pa­
tients, after 4 shocks (50,100, 200, and 360 J) in 43 pa­
tients, and after 5 shocks (50,100,200, and twice 360J) 
in 5 patients. In the other 93 patients, sinus rhythm was 
notrestor
of energy. Multivariate analysis revealed that only the pre­
vious arrhythmia duration was associated with failure to 
establish sinus rhythm. Previous atrial fibri 
a duration of 3 to 36 months and exceeding .36 months 
was associated with a 4-fold (95% CI, 2-11; P=.003) and
ate analysis.
CARDIOVASCULAR EVENTS
ar events are in Table 4
these are stratified to the presen ce of risk factors that are
of the serial cardioversion strat­
egy. It can be readi 
rose sharply in line with the number of arrhythmia risk 
factors. Congestive heart failure and cardiovascular death
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Chronic AF
I
-*> ECV
SR
"Late’1 REC
Mo AADs
SR "Early” REC 4 Weeks of 
Amiodarone Therapy
‘late’’ REC SR
Sotalol Hydrochloride
SR "Early” REC
T
ECV
AF
Amiodarone
Therapy
Continued
Accept AF
"Late” REC
Flecalnlde Acetate
SR "Early” REC
4 Weeks of Amiodarone Therapy
Accept AF
"Late" REC
Amiodarone Therapy 
Continued
Figure 1. Serial electrical cardioversion protocol, AADs indicates 
antiarrhythmic drugs; AF, atrial fibrillation; "early" REC, recurrence within 1 
year; ECV, electrical cardioversion; "late" REC, recurrence after 1 year; and 
SR, sinus rhythm.
were the most frequent events. Two patients were ad­
mitted to the neurology department because of non fatal 
ischemic strokes at 689 and 430 days after restoration 
of sinus rhythm. At that time, they both showed a recur­
rence of atrial fibrillation, while they were not being
was a
year-old woman with a history of hypertension who suf­
fered from a hemiparesis. Previous echocardiography 
showed a normal, left ventricular function and a left atrial 
size within, the normal range. She recovered almost com­
pletely. The second patient was a 74-year-old man with 
a history of coronary artery disease who had a hemipa- 
ralysis. Previously, his left ventricular function was nor­
mal, but the left atrium was slightly enlarged. He did not 
recover from the hemiparalysis. Neither of these pa­
tients suffered an earlier thromboembolic event. The to­
tal incidence of thromboembolic complications per pa- 
tient-year in our study amounted to 0.2%. A comparison 
with the findings of other studies is given in Table 5. 
Hemorrhagic complications that led to a hospital admis­
sion occurred in 13 patients during total follow-up; all
occurred while they were receiving coumarin and after 
a mean±SD of 302±199 days after inclusion. Two pa­
tients suffered a hemorrhagic stroke; in 1 of these pa­
tients, it was fatal. Ten patients, of whom 1. died, had 
bleeding of the gastrointestinal tract. Another patient suf­
fered from a traumatic hemarthrosis. The total inci­
dence of hemorrhagic complications was 1.5 per 100 pa- 
tient-years; this figure is in good agreement with that of 
other studies in patients with atrial fibrillation (Table 5). 
No patient experienced a fall during the study. Overt 
symptoms of congestive heart failure were frequent dur­
ing follow-up and occurred predominantly in those pa­
tients with preexisting heart failure and other risk fac­
tors for atrial fibrillation. Eleven serious adverse events 
that related to antiarrhythmic drug use were encoun­
tered. Each of these events led to withdrawal of the agent: 
5 times for amiodarone because of hypothyroidism or skin 
photoallergy, 3 times for sotalol because of symptom­
atic hypotension or nightmares, 2 times for flecainidc be­
cause of progression of congestive heart failure and ex­
cessive QRS prolongation, and, finally, once due to digitalis 
intoxication complicated by paroxysmal atrial tachycar­
dia in a patient with accepted atrial fibrillation. Ventricu­
lar proarrhythmia did not occur. Five patients under­
went pacemaker implantation: 2 because of sick sinus 
syndrome and 3 prior to bundle of His ablation. During 
follow-up, 39 patients (16.5%) died. Mortality was of a 
cardiovascular origin in 31 patients (13.5%), and 9 of them 
died suddenly.
COMMENT
In this large-scale prospective study, the efficacy of se­
rial cardioversions in the management of chronic atrial 
fibrillation was determined during long-term follow- 
up. Whereas the majority of patients with chronic atrial 
fibrillation failed to respond to our serial cardioversion 
strategy, acceptance of the arrhythmia was postponed in 
many patients who maintained sinus rhythm for some 
additional years. It is likely that the latter group of pa­
tients benefited because they were exposed for a shorter 
time to the deleterious effects that related to the arrhyth­
mia. We also demonstrated that both the fate of atrial fi­
brillation and the risk of cardiovascular events are. de-
;: duration of the arrhythmia, 
presence of heart failure, and age. Finally, the present data 
support the notion that chronic atrial fibrillation treated 
by serial electrical cardioversion in combination with well- 
monitored oral anticoagulation is associated wilh few
'  f%
I
Like previous studies, we also showed that an in­
creasing duration of atrial fibrillation inversely corre­
lates with the chance of reinstitution of sinus rhythm.2 5'2'’ 
Unexpectedly, however, a duration of atrial fibrillation
as short as 3 months impaired the success of the serial
i
cardioversion therapy. Perhaps this already is related to 
generated permanent morphological changes in the atria 
at that time, whereas tachycardia-induced changes (eg,
*27) are pi more eas revers-
ible. The obvious clinical consequence is that cardiover­
sion should be performed as early as possible after onset 
of the arrhythmia, preferably within 3 months. In this
ARCH INTERN MED/VOL 156, DEC 9/23, 1996
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Table 1. Baseline Characteristics of Patients With a Successful Serial Cardioversion 
Approach vs Patients in Whom This Approach Failed
Patients
Characteristic
V"
No. of patients 
Mean±SD age, y 
Age, yt
s56
57-63
64-70
2:71
Sex ratio, M/F
Underlying heart disease, % of patients^  
Coronary artery disease 
' Rheumatic heart disease 
Nonrheumatic valvular heart dlsease§
Chronic obstructive pulmonary disease
Cardiomyopathy
Congenital heart disease
“Lone" atrial fibrillation
Miscellaneous!!
Duration of atrial fibrillation, mofl 
<3 
3-9 
9-36 
2:36
New York Heart Association, %
Class I 
Class II 
Class III
Mean±SD dimensions, mm 
L atrial size 
R atrial size
L ventricular end-diastolic diameter 
L ventricular end-systolic diameter
Total
Group
236
63±12
27 
21 
27 
25 
133:103
28
17
16
17
8
7
3
22
3
9
25
26 
23 
26
31
45
24
46±8 
61 ±8
53±9..-,-
38±10
Success 
With Serial 
Cardioversion
74
60±13
44 
20 
20 
16 
41:33
27
11
21
14
8
10
0
26
1
4
39
27
24
10
34
53
13
44 ± 6
59±8
52±9
37±10
----------------------------------- !
Failure 
With Serial 
Cardioversion
162 
64±12
24
21
28
27
92:70
28
20
13
18
9
6
4
20
4
20
22
26
24
28
30
42
28
47±8
62±8
53±9
38±10
mi.
P *
I  «  *
.02
« « »
a 4 «
I  % *
4 I  I
.89
,79
,21
.29
.37
.79
.36
.03
.26
.31
.001
*  • r
» * 4
♦ * 4
♦ » i
.02
< * f
» t  i
.02
.01
.67
.57
‘"P value of univariate analysis is shown, 
t Data for the age ranges are given as the percentages of patients.
\.More than 1 underlying disease per patient was scored,
§Nonrheumatic valvular heart disease included atherosclerotic mitral regurgitation, 13 patients; mitral regurgitation due to chorda rupture, 1 patient; congenital 
mitral stenosis plus valve replacement, 1 patient; mitral valve prolapse, 4 patients; aortic regurgitation, 6 patients; and aortic stenosis, 11 patients.
||Miscellaneous included 2 patients after corrected hyperthyroidism, 3 patients with sick sinus syndrome and with an artificial pacemaker, 1 patient after 
pulmonary surgery, and 1 patient with alcohol abuse.
M^edian values are given; data for the month ranges are given as the percentages of patients.
tern of relapses in the course of follow-up has been re­
ported for disopyramide phosphate, flecainide, propafe­
none hydrochloride, sotalol, and amiodarone.1 iU u 'u i 
Thus, the duration of follow-up has often been loo short 
to qualify correctly patients as being “cured,” because 
The low efficacy of the single-shock approach for many will suffer a relapse of the arrhythmia after the fol- 
restoration and maintenance of sinus rhythm is in con- low-up period. From our study, it may also he learned
. . - . M i
regard,
hanced by patient counseling, including explanation of 
the symptoms suggestive for recurrence, of the arrhyth­
mia, and if that is the matter, to realize an urgent ap-
trast with previous findings. This may be explained by that patients younger than 57 years with a duration of
other investigators’ exclusion of patients for whom an ini- atrial fibrillation of less than 36 months and without hy- 
tial cardioversion failed. In contrast, our study included pertension are likely to he cured of chronic atrial fibril
patients in whom sinus rhythm could not be restored af- lation after only 1 shock and without the start of therapy 
ter a single cardioversion. Second, the duration of fol- with an antiarrhythmie drug. Although this group rep- 
low-up was shorter in other studies compared with that 
of the present study. Recently, Coplen et al11 summa­
rized 6 quinidine studies and reported that 69%, 58%, 
and 50%) of patients maintained sinus rhythm for 3, 6,
resented only 10% of the present population, costs and 
isles for these patients can he dramatically reduced by
using the electrical cardioversion approach.
The impact of prophylactic antiarrhythm ie drugs ap- 
and 12 months, respectively. A similar progressive pat- pears to he limited. Only some patients have responded
ARCH INTERN MED/VOL 156, DEC 0/2), 199b
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Figure 2. Kaplan-Meier plots depicting the probability of maintenance of 
sinus rhythm (SR) after serial electrical cardioversions (>-1 electrical 
cardioversion [ECV]) compared with a single cardioversion without drug 
prescription (1 ECV). N indicates the number of patients at risk during 
serial cardioversion therapy.
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Figure 4. Kaplan-Meier plots depicting the probability of maintenat 
sinus rhythm (SR) after serial cardioversions in relation to the prei 
risk factors (previous arrhythmia duration >36 months; functional 
ill; and age >56 years). RF indicates risk factor.
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Figure 3. Cumulative number of patients in sinus rhythm classified 
according to the number of electrical cardioversions (ECV) and type of 
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Table 2. Results of Cox Proportional Hazards Regression 
Analysis: Risk on Failure of Serial Cardioversion Therapy
Risk Factor
Adjusted 
Risk Ratio
95%
Confidence
Interval P
tmm
Duration of atrial fibrillation, mo* 
3-35
2:36
New York Heart Association class 
lilt 
Age >56 y±
2.1 1.3-3.4 .002
5.0 3.0-8.3 <.001
1.8 1.3-2.6 .001
1.5 1.0-2.2 .04
* Reference category atrial fibrillation duration less than 3 months with 
an adjusted risk ratio of 1.0.
t Reference category New York Heart Association classes I and II with 
an adjusted risk ratio of 1.0.
:(:Reference category age of 56 years or younger with an adjusted risk 
ratio of 1.0.
Table 3. Results of Cox Proportional Hazards Regressi 
Analysis: Risk on Failure of Maintenance of Sinus 
Rhythm After the Single Cardioversion Procedure
Adjusted 95% 
Risk Contidence
Risk Factor Ratio Interval
Duration of atriai fibrillation s:36 mo* 
Age >56 yf 
Hypertension present
2.5
1.5
1.5
1.8-3.4 
1.1-2,1 
1.1-2.2
<
* Reference category atrial fibrillation duration less than 36 mont 
an adjusted risk ratio of 1.0.
t Reference category age of 56 years or younger with an adjuste 
ratio of 1.0.
to . On the
amiodarone was rather successful; this finding
of earlier reports.7,tUJ It is i 
sible to draw conclusions concerning the proph; 
efficacy of these drugs because the present stuc 
not a random ized  one, and there was no cc
The hypothesis that our serial cardioversic 
proach, in combination with a relatively high level
ation, may restrict 0111
bolic events w ithout increasing the rate of ble 
complications was supported by comparison of oi 
with those of other trials on the effects of antit’ 
botic therapy in patients with accepted atrial fibril 
(Table 5). Excep t for a somewhat younger mean age 
characteristics such as the presence of congestive 
failure and left atrial size were about similar in o 
tients compared with those of the other recent st 
Thus, we believe that our results may not be ascri 
a favorable selection of patients. Currently, the is
ARCH INTERN MED/VOL 156, DEC 9/23, 19%
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Table 4. Major Cardiovascular Events in Relation to the Presence of the Arrhythmia Risk Factors*
No. (%) o! Patients
Cardiovascular Event
. . wmtnm ■!■■■ — ..............  ■■■.... — , ■ -------n--- | | - |
Ischemic thromboembolic complication 
Hemorrhagic complications, including hemorrhagic stroke 
Congestive heart failure, including valvular surgery 
Adverse events caused by antiarrhythmlc drugs 
Pacemaker Implantation 
Cardiovascular death
Total Group No Risk Factor
1 Risk 
Factor
1
2 Risk Factors
(N=236) (n=39) (n=108) (n=89)
2(1) 0 2(2) 0
13 (5.5), 2(1) 0,0 10 (9), 2 (2) 3 (3.5), 0
33 (14), 8 (3.5) 3 (7.5), 1 (2.5) 10 (9), 3 (3) 20 (22.5), 4 (4.5)
11(5) 0 8 (7.5) 3 (3.5)
5 (2.5) 0 3(3) 2(2)
31(13.5) 3 (7,5) 8 (7.5) 20 (22.5)
95 (41.5) 6(15) 41 (38) 48 (54)
_uiijM«)i»jJ ii>i M 'ì r >» rw in i[)iiiiir >iti>iiiir-iiTTiiiìtiTn>iiTiTiìffinTiii-ì,iiiiiirimrr«niiiiiirn ii ìiiirtw
*Risk factors were a duration of atrial fibrillation of 36 months or greater, functional New York Heart Association class III, and age older than 56 years.
Table 5, Incidence of Embolic and Bleeding Complications During the Present Study Compared With That of Previous Studies*
% of Patients
No. of Mean Mean
Mean L 
Atrial
Chronic
Atrial
Congestive
Heart TECs / Bleeding/
Source, y Patients INR Follow-up, y Patient-Years Age, y Size, mm Fibrillation Failure Patient-Years Patient-Yearst
Petersen et al,171989 335 2.8:4,2 2 413 73 « « « 100 50 1.2 2,7
SPAF I,1» 1991 210 2.0:4.5 1.3 263 65 46 62 14 2.3 1,5
BAATAF,191990 212 1.5:2.7 2.3 487 69 42 83 24 0.4 1.6
Connolly et al,M 1991 187 2.0:3.0 1.3 237 68 46 94 24 2.5 2,1
Ezekowitz et al,211992 260 1.5:2.7 1.8 489 67 * t  t 100 31 0.9 1.5
SPAF II,221994 •
Age, 2£75 y 358 2.0:4.5 3.1 1110 64 • * m 1 1 ^ 17 1.3 1.7
Age, >75 y 197 2.0:4.5 2.0 394 80 % M 4 52 3.6 4.2
Present study 236 2.4:4.8 3.7 873 63 46 100 69 0.2 1.5
*****
*0nly subgroups that were treated with oral anticoagulants were used for comparison. INR indicates international normalized ratio; TECs, thromboembolic 
complications; SPAF I, Stroke Prevention in Atrial Fibrillation Study I; BAATAF, Boston Area Anticoagulation Trial for Atrial Fibrillation; and SPAF il, Stroke 
Prevention in Atrial Fibrillation Study II.
■\Bleeding complications that necessitated hospitalization.
** ¿ A tiled whether a serial electrical cardioversion strat- ment of the latter group may further be obtained by more
t hat is aimed at maintaining sinus rhythm reduces frequent patient counseling and explanation of the symp-
or mortality in patients with chronic atrial fi- toms associated with a recurrence of the arrhythmia so that
alion. To deal with this problem, a controlled com- they may seek professional care earlier (ie, when the con-
of cardioversion vs rate control treatment has re- 
cn suggested.2H Obviously, that study should 
are morbidity and mortality, but it should also com­
pare the costs of treatment and quality of life.
summary
s (age <57 years) with atrial fibrillation of less than 
duration and a fair exercise tolerance (New 
Heart Association functional class I or II) but with-
ditions for electrical cardioversion are most optimal).
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rsion, There is no need to treat
prophylactic antiarrhythmic drugs. On the other hand,
patients (age >70 years) with a duration of atrial fibrilla- pital Groningen, PO Box 30.001, 9700 RB Groningen, the 
lion that exceeds 36 months and a poor exercise toler- Netherlands. 
ance (New York Heart Association functional class III or 
IV). Finally, the serial electrical cardioversion approach 
with the start of therapy with prophylactic antiarrhyth­
mic drugs is worthwhile in patients younger than 71 years 
who have a duration of atrial fibrillation of less than 36
months and a fair
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